ASH: Eli Lilly touts novel BTK trial win for Jaypirca as execs defend survival data blemish

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated approval—which allows the BTK inhibitor to be used following another drug in the class—into a full nod.